China Medical System (HKG:0867) said its Lumirix ruxolitinib phosphate cream has been approved in China.
The cream is used for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients, according to a Thursday filing.
The National Medical Products Administration approved the new drug application on Wednesday, and obtained the drug registration certificate on Thursday.